<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;ff=20230831100752&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;ff=20230831100752&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 31 Aug 2023 14:07:55 +0000</lastbuilddate>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Optimal Measurement of Coronary Flow and Microvascular Function in Animals and Humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37650288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 31. doi: 10.1161/CIRCRESAHA.123.323341. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37650288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37650288</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323341>10.1161/CIRCRESAHA.123.323341</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37650288</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Lennert Minten</dc:creator>
<dc:creator>Michiel Algoet</dc:creator>
<dc:creator>Johan Bennett</dc:creator>
<dc:creator>Wouter Oosterlinck</dc:creator>
<dc:creator>Bart Meuris</dc:creator>
<dc:creator>Tom Langenaeken</dc:creator>
<dc:creator>Stephanie Bézy</dc:creator>
<dc:creator>Laurine Wouters</dc:creator>
<dc:creator>Jürgen Duchenne</dc:creator>
<dc:creator>Alexis Puvrez</dc:creator>
<dc:creator>Senne de Groote</dc:creator>
<dc:creator>Pierluigi Lesizza</dc:creator>
<dc:creator>Pascal Frederiks</dc:creator>
<dc:creator>Laurens de Vos</dc:creator>
<dc:creator>Tom Adriaenssens</dc:creator>
<dc:creator>Peter Sinnaeve</dc:creator>
<dc:creator>Walter Desmet</dc:creator>
<dc:creator>Keir McCutcheon</dc:creator>
<dc:creator>Christophe Dubois</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Optimal Measurement of Coronary Flow and Microvascular Function in Animals and Humans</dc:title>
<dc:identifier>pmid:37650288</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323341</dc:identifier>
</item>
<item>
<title>Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37650264/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: A real-time, targeted, and tailored EHR-based alert system for AHF did not lead to a higher number of overall GDMT prescriptions at discharge. Further refinement and improvement of such alerts and changes to clinician incentives are needed to overcome barriers to the implementation of GDMT during hospitalizations for AHF. GDMT remains suboptimal in this setting, with only one in nine patients being discharged on a comprehensive evidence-based regimen for heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 31:ehad512. doi: 10.1093/eurheartj/ehad512. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients hospitalized for acute heart failure (AHF) continue to be discharged on an inadequate number of guideline-directed medical therapies (GDMT) despite evidence that inpatient initiation is beneficial. This study aimed to examine whether a tailored electronic health record (EHR) alert increased rates of GDMT prescription at discharge in eligible patients hospitalized for AHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pragmatic trial of messaging to providers about treatment of acute heart failure (PROMPT-AHF) was a pragmatic, multicenter, EHR-based, and randomized clinical trial. Patients were automatically enrolled 48 h after admission if they met pre-specified criteria for an AHF hospitalization. Providers of patients in the intervention arm received an alert during order entry with relevant patient characteristics along with individualized GDMT recommendations with links to an order set. The primary outcome was an increase in the number of GDMT prescriptions at discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Thousand and twelve patients were enrolled between May 2021 and November 2022. The median age was 74 years; 26% were female, and 24% were Black. At the time of the alert, 85% of patients were on β-blockers, 55% on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, 20% on mineralocorticoid receptor antagonist (MRA) and 17% on sodium-glucose cotransporter 2 inhibitor. The primary outcome occurred in 34% of both the alert and no alert groups [adjusted risk ratio (RR): 0.95 (0.81, 1.12), P = .99]. Patients randomized to the alert arm were more likely to have an increase in MRA [adjusted RR: 1.54 (1.10, 2.16), P = .01]. At the time of discharge, 11.2% of patients were on all four pillars of GDMT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A real-time, targeted, and tailored EHR-based alert system for AHF did not lead to a higher number of overall GDMT prescriptions at discharge. Further refinement and improvement of such alerts and changes to clinician incentives are needed to overcome barriers to the implementation of GDMT during hospitalizations for AHF. GDMT remains suboptimal in this setting, with only one in nine patients being discharged on a comprehensive evidence-based regimen for heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37650264/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37650264</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad512>10.1093/eurheartj/ehad512</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37650264</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Lama Ghazi</dc:creator>
<dc:creator>Yu Yamamoto</dc:creator>
<dc:creator>Michael Fuery</dc:creator>
<dc:creator>Kyle O'Connor</dc:creator>
<dc:creator>Sounok Sen</dc:creator>
<dc:creator>Marc Samsky</dc:creator>
<dc:creator>Ralph J Riello</dc:creator>
<dc:creator>Ravi Dhar</dc:creator>
<dc:creator>Joanna Huang</dc:creator>
<dc:creator>Temitope Olufade</dc:creator>
<dc:creator>James McDermott</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Francis Perry Wilson</dc:creator>
<dc:creator>Nihar R Desai</dc:creator>
<dc:creator>Tariq Ahmad</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial</dc:title>
<dc:identifier>pmid:37650264</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad512</dc:identifier>
</item>
<item>
<title>Intranasal 'spray-in-the-pocket' treatment for conversion of supraventricular tachycardia: safe, effective but not definite</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37650261/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 31:ehad502. doi: 10.1093/eurheartj/ehad502. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37650261/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37650261</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad502>10.1093/eurheartj/ehad502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37650261</guid>
<pubDate>Thu, 31 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Maria Lucia Narducci</dc:creator>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:date>2023-08-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intranasal 'spray-in-the-pocket' treatment for conversion of supraventricular tachycardia: safe, effective but not definite</dc:title>
<dc:identifier>pmid:37650261</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad502</dc:identifier>
</item>
<item>
<title>Reply: Nonculprit Lesion Location and Outcomes From the CULPRIT-SHOCK Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648361/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):e87-e88. doi: 10.1016/j.jacc.2023.06.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648361/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648361</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.028>10.1016/j.jacc.2023.06.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648361</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Uwe Zeymer</dc:creator>
<dc:creator>Taoufik Ouarrak</dc:creator>
<dc:creator>Steffen Desch</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Nonculprit Lesion Location and Outcomes From the CULPRIT-SHOCK Trial</dc:title>
<dc:identifier>pmid:37648361</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.028</dc:identifier>
</item>
<item>
<title>Nonculprit Lesion Location and Outcomes From the CULPRIT-SHOCK Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648360/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):e85. doi: 10.1016/j.jacc.2023.04.062.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648360/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648360</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.062>10.1016/j.jacc.2023.04.062</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648360</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ahmed Elkaryoni</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Nonculprit Lesion Location and Outcomes From the CULPRIT-SHOCK Trial</dc:title>
<dc:identifier>pmid:37648360</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.062</dc:identifier>
</item>
<item>
<title>Mortality Trends After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In a high-income European country with a fully implemented pPCI strategy, 1-year mortality in pPCI-treated patients with STEMI decreased substantially between 2003 and 2018. Approximately three-quarters of the absolute mortality reduction occurred within the first 30 days after pPCI. These results indicate that optimization of early management of pPCI-treated patients with STEMI offers great opportunities for improving overall survival in contemporary clinical practice.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):999-1010. doi: 10.1016/j.jacc.2023.06.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Observational studies have reported that mortality rates after ST-segment elevation myocardial infarction (STEMI) have been stable since 2006 to 2010.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate the temporal trends in 1-year, 30-day, and 31- to 365-day mortality after STEMI in Western Denmark where primary percutaneous coronary intervention (PCI) has been the national reperfusion strategy since 2003.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Western Denmark Heart Registry, the study identified first-time PCI-treated patients undergoing primary PCI (pPCI) for STEMI from 2003 to 2018. Based on the year of pPCI, patients were divided into 4 time-interval groups and followed up for 1 year using the Danish national health registries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 19,613 patients were included. Median age was 64 years, and 74% were male. One-year mortality decreased gradually from 10.8% in 2003-2006, 10.4% in 2007-2010, 9.1% in 2011-2014, to 7.7% in 2015-2018 (2015-2018 vs 2003-2006: adjusted HR [aHR]: 0.71; 95% CI: 0.62-0.82). The largest absolute mortality decline occurred in the 0- to 30-day period with a 2.3% reduction (aHR: 0.69; 95% CI: 0.59-0.82), and to a lesser extent in the 31- to 365-day period (risk reduction: 1.0%; aHR: 0.71; 95% CI: 0.56-0.90).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a high-income European country with a fully implemented pPCI strategy, 1-year mortality in pPCI-treated patients with STEMI decreased substantially between 2003 and 2018. Approximately three-quarters of the absolute mortality reduction occurred within the first 30 days after pPCI. These results indicate that optimization of early management of pPCI-treated patients with STEMI offers great opportunities for improving overall survival in contemporary clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648359</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.025>10.1016/j.jacc.2023.06.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648359</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Pernille Gro Thrane</dc:creator>
<dc:creator>Kevin Kris Warnakula Olesen</dc:creator>
<dc:creator>Troels Thim</dc:creator>
<dc:creator>Christine Gyldenkerne</dc:creator>
<dc:creator>Martin Bødtker Mortensen</dc:creator>
<dc:creator>Steen Dalby Kristensen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mortality Trends After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction</dc:title>
<dc:identifier>pmid:37648359</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.025</dc:identifier>
</item>
<item>
<title>Cardiogenic Shock: Lessons From Hurricanes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):996-998. doi: 10.1016/j.jacc.2023.06.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648358</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.027>10.1016/j.jacc.2023.06.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648358</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>David A Baran</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiogenic Shock: Lessons From Hurricanes</dc:title>
<dc:identifier>pmid:37648358</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.027</dc:identifier>
</item>
<item>
<title>Long-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Short- and long-term mortality among patients with AMI-CS is high, with minimal improvement over time. AMI-CS survivors experience significant morbidity, with high risks of readmission and death. Future studies should evaluate interventions to minimize postdischarge morbidity and mortality among AMI-CS survivors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):985-995. doi: 10.1016/j.jacc.2023.06.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiogenic shock secondary to acute myocardial infarction (AMI-CS) is associated with substantial short-term mortality; however, there are limited data on long-term outcomes and trends.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to examine long-term outcomes of AMI-CS patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a population-based, retrospective cohort study in Ontario, Canada of critically ill adult patients with AMI-CS who were admitted to hospitals between April 1, 2009 and March 31, 2019. Outcome data were captured using linked health administrative databases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 9,789 consecutive patients with AMI-CS from 135 centers were included. The mean age was 70.5 ± 12.3 years, and 67.7% were male. The incidence of AMI-CS was 8.2 per 100,000 person-years, and it increased over the study period. Critical care interventions were common, with 5,422 (55.4%) undergoing invasive mechanical ventilation, 1,425 (14.6%) undergoing renal replacement therapy, and 1,484 (15.2%) receiving mechanical circulatory support. A total of 2,961 patients (30.2%) died in the hospital, and 4,004 (40.9%) died by 1 year. Mortality at 5 years was 58.9%. Small improvements in short- and long-term mortality were seen over the study period. Among survivors to discharge, 2,870 (42.0%) required increased support in care from their preadmission baseline, 3,244 (47.5%) were readmitted to the hospital within 1 year, and 1,047 (15.3%) died within 1 year. The mean number of days at home in the year following discharge was 307.9 ± 109.6.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Short- and long-term mortality among patients with AMI-CS is high, with minimal improvement over time. AMI-CS survivors experience significant morbidity, with high risks of readmission and death. Future studies should evaluate interventions to minimize postdischarge morbidity and mortality among AMI-CS survivors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648357/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648357</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.026>10.1016/j.jacc.2023.06.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648357</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Lee H Sterling</dc:creator>
<dc:creator>Shannon M Fernando</dc:creator>
<dc:creator>Robert Talarico</dc:creator>
<dc:creator>Danial Qureshi</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>Margaret S Herridge</dc:creator>
<dc:creator>Susanna Price</dc:creator>
<dc:creator>Daniel Brodie</dc:creator>
<dc:creator>Eddy Fan</dc:creator>
<dc:creator>Pietro Di Santo</dc:creator>
<dc:creator>Richard G Jung</dc:creator>
<dc:creator>Simon Parlow</dc:creator>
<dc:creator>Mir B Basir</dc:creator>
<dc:creator>Damon C Scales</dc:creator>
<dc:creator>Alain Combes</dc:creator>
<dc:creator>Rebecca Mathew</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Peter Tanuseputro</dc:creator>
<dc:creator>Benjamin Hibbert</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction</dc:title>
<dc:identifier>pmid:37648357</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.026</dc:identifier>
</item>
<item>
<title>Managing Myocardial Infarction in the Age of Multimorbidity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):982-984. doi: 10.1016/j.jacc.2023.06.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648356</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.023>10.1016/j.jacc.2023.06.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648356</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Fanaroff</dc:creator>
<dc:creator>Michela Faggioni</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Managing Myocardial Infarction in the Age of Multimorbidity</dc:title>
<dc:identifier>pmid:37648356</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.023</dc:identifier>
</item>
<item>
<title>Temporal Trends in Noncardiovascular Morbidity and Mortality Following Acute Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Although cardiovascular mortality following MI improved substantially during 2000 to 2017, the risk of noncardiovascular morbidity increased. Moreover, noncardiovascular causes constitute an increasing proportion of post-MI mortality. These findings suggest that further attention on noncardiovascular outcomes is warranted in guidelines and clinical practice and should be considered in the design of future clinical trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):971-981. doi: 10.1016/j.jacc.2023.06.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Due to improved management, diagnosis, and care of myocardial infarction (MI), patients may now survive long enough to increasingly develop serious noncardiovascular conditions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to test this hypothesis by investigating the temporal trends in noncardiovascular morbidity and mortality following MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a registry-based nationwide cohort study of all Danish patients with MI during 2000 to 2017. Outcomes were cardiovascular and noncardiovascular mortality, incident cancer, incident renal disease, and severe infectious disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 2000 to 2017, 136,293 consecutive patients were identified (63.2% men, median age 69 years). The 1-year risk of cardiovascular mortality between 2000 to 2002 and 2015 to 2017 decreased from 18.4% to 7.6%, whereas noncardiovascular mortality decreased from 5.8% to 5.0%. This corresponded to an increase in the proportion of total 1-year mortality attributed to noncardiovascular causes from 24.1% to 39.5%. Furthermore, increases in 1-year risk of incident cancer (1.9%-2.4%), incident renal disease (1.0%-1.6%), and infectious disease (5.5%-9.1%) were observed (all P trend &lt;0.01). In analyses standardized for changes in patient characteristics, the increased risk of cancer in 2015 to 2017 compared with 2000 to 2002 was no longer significant (standardized risk ratios for cancer: 0.99 [95% CI: 0.91-1.07]; renal disease: 1.28 [95% CI: 1.15-1.41]; infectious disease: 1.28 [95% CI: 1.23-1.34]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although cardiovascular mortality following MI improved substantially during 2000 to 2017, the risk of noncardiovascular morbidity increased. Moreover, noncardiovascular causes constitute an increasing proportion of post-MI mortality. These findings suggest that further attention on noncardiovascular outcomes is warranted in guidelines and clinical practice and should be considered in the design of future clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648355</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.024>10.1016/j.jacc.2023.06.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648355</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniel Mølager Christensen</dc:creator>
<dc:creator>Jarl Emanuel Strange</dc:creator>
<dc:creator>Mohamad El-Chouli</dc:creator>
<dc:creator>Alexander Christian Falkentoft</dc:creator>
<dc:creator>Morten Malmborg</dc:creator>
<dc:creator>Nina Nouhravesh</dc:creator>
<dc:creator>Gunnar Gislason</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Thomas S G Sehested</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Temporal Trends in Noncardiovascular Morbidity and Mortality Following Acute Myocardial Infarction</dc:title>
<dc:identifier>pmid:37648355</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.024</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):1051. doi: 10.1016/j.jacc.2023.07.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648354/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648354</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.009>10.1016/j.jacc.2023.07.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648354</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:37648354</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.009</dc:identifier>
</item>
<item>
<title>Ablation to Reduce Atrial Fibrillation Burden and Improve Outcomes: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>Atrial fibrillation is the most common atrial arrhythmia and accounts for a significant burden of cardiovascular disease globally. With advances in implanted and wearable cardiac monitoring technology, it is now possible to readily and accurately quantify an individual's time spent in atrial fibrillation. This review summarizes the relationship between atrial fibrillation burden and adverse cardiovascular and cerebrovascular outcomes and discusses the role of catheter ablation to mitigate the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):1039-1050. doi: 10.1016/j.jacc.2023.06.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation is the most common atrial arrhythmia and accounts for a significant burden of cardiovascular disease globally. With advances in implanted and wearable cardiac monitoring technology, it is now possible to readily and accurately quantify an individual's time spent in atrial fibrillation. This review summarizes the relationship between atrial fibrillation burden and adverse cardiovascular and cerebrovascular outcomes and discusses the role of catheter ablation to mitigate the morbidity and mortality associated with greater burden of atrial fibrillation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648353</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.029>10.1016/j.jacc.2023.06.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648353</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Hannah T Schwennesen</dc:creator>
<dc:creator>Jason G Andrade</dc:creator>
<dc:creator>Kathryn A Wood</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ablation to Reduce Atrial Fibrillation Burden and Improve Outcomes: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37648353</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.029</dc:identifier>
</item>
<item>
<title>Impact of Sex on Cardiovascular Adaptations to Exercise: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>Routine exercise leads to cardiovascular adaptations that differ based on sex. Use of cardiac testing to screen athletes has driven research to define how these sex-based adaptations manifest on the electrocardiogram and cardiac imaging. Importantly, sex-based differences in cardiovascular structure and outcomes in athletes often parallel findings in the general population, underscoring the importance of understanding their mechanisms. Substantial gaps exist in the understanding of why...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):1030-1038. doi: 10.1016/j.jacc.2023.05.070.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Routine exercise leads to cardiovascular adaptations that differ based on sex. Use of cardiac testing to screen athletes has driven research to define how these sex-based adaptations manifest on the electrocardiogram and cardiac imaging. Importantly, sex-based differences in cardiovascular structure and outcomes in athletes often parallel findings in the general population, underscoring the importance of understanding their mechanisms. Substantial gaps exist in the understanding of why cardiovascular adaptations and outcomes related to exercise differ by sex because of underrepresentation of female participants in research. As female sports participation rates have increased dramatically over several decades, it also remains unknown if differences observed in older athletes reflect biological mechanisms vs less lifetime access to sports in females. In this review, we will assess the effect of sex on cardiovascular adaptations and outcomes related to exercise, identify the impact of sex hormones on exercise performance, and highlight key areas for future research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648352</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.070>10.1016/j.jacc.2023.05.070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648352</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Bradley J Petek</dc:creator>
<dc:creator>Eugene H Chung</dc:creator>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Dermot Phelan</dc:creator>
<dc:creator>Alfred Danielian</dc:creator>
<dc:creator>Peter N Dean</dc:creator>
<dc:creator>Elizabeth H Dineen</dc:creator>
<dc:creator>Antonio B Fernandez</dc:creator>
<dc:creator>Mustafa Husaini</dc:creator>
<dc:creator>Sheela Krishnan</dc:creator>
<dc:creator>Ankit B Shah</dc:creator>
<dc:creator>Katie M Stewart</dc:creator>
<dc:creator>Meagan M Wasfy</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Sex on Cardiovascular Adaptations to Exercise: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37648352</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.070</dc:identifier>
</item>
<item>
<title>STEMI-Related Mortality: Don't Stop Believin'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37648351/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 5;82(10):1011-1013. doi: 10.1016/j.jacc.2023.07.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37648351/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37648351</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.007>10.1016/j.jacc.2023.07.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37648351</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Timothy D Henry</dc:creator>
<dc:creator>Suzanne J Baron</dc:creator>
<dc:creator>Alice K Jacobs</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>STEMI-Related Mortality: Don't Stop Believin'</dc:title>
<dc:identifier>pmid:37648351</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.007</dc:identifier>
</item>
<item>
<title>Stroke risk in women with atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37647629/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: Older age and inequities in cardiovascular care may partly explain higher stroke rates in females with AF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 30:ehad508. doi: 10.1093/eurheartj/ehad508. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Female sex is associated with higher rates of stroke in atrial fibrillation (AF) after adjustment for other CHA2DS2-VASc factors. This study aimed to describe sex differences in age and cardiovascular care to examine their relationship with stroke hazard in AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Population-based cohort study using administrative datasets of people aged ≥66 years diagnosed with AF in Ontario between 2007 and 2019. Cause-specific hazard regression was used to estimate the adjusted hazard ratio (HR) for stroke associated with female sex over a 2-year follow-up. Model 1 included CHA2DS2-VASc factors, with age modelled as 66-74 vs. ≥ 75 years. Model 2 treated age as a continuous variable and included an age-sex interaction term. Model 3 further accounted for multimorbidity and markers of cardiovascular care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The cohort consisted of 354 254 individuals with AF (median age 78 years, 49.2% female). Females were more likely to be diagnosed in emergency departments and less likely to receive cardiologist assessments, statins, or LDL-C testing, with higher LDL-C levels among females than males. In Model 1, the adjusted HR for stroke associated with female sex was 1.27 (95% confidence interval 1.21-1.32). Model 2 revealed a significant age-sex interaction, such that female sex was only associated with increased stroke hazard at age >;70 years. Adjusting for markers of cardiovascular care and multimorbidity further decreased the HR, so that female sex was not associated with increased stroke hazard at age ≤80 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Older age and inequities in cardiovascular care may partly explain higher stroke rates in females with AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37647629/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37647629</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad508>10.1093/eurheartj/ehad508</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37647629</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Hifza Buhari</dc:creator>
<dc:creator>Jiming Fang</dc:creator>
<dc:creator>Lu Han</dc:creator>
<dc:creator>Peter C Austin</dc:creator>
<dc:creator>Paul Dorian</dc:creator>
<dc:creator>Cynthia A Jackevicius</dc:creator>
<dc:creator>Amy Y X Yu</dc:creator>
<dc:creator>Moira K Kapral</dc:creator>
<dc:creator>Sheldon M Singh</dc:creator>
<dc:creator>Karen Tu</dc:creator>
<dc:creator>Dennis T Ko</dc:creator>
<dc:creator>Clare L Atzema</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Douglas S Lee</dc:creator>
<dc:creator>Husam Abdel-Qadir</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Stroke risk in women with atrial fibrillation</dc:title>
<dc:identifier>pmid:37647629</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad508</dc:identifier>
</item>
<item>
<title>Atherosclerotic Coronary Plaque Regression and Risk of Adverse Cardiovascular Events: A Systematic Review and Updated Meta-Regression Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37647074/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this meta-analysis, regression of atherosclerotic plaque by 1% was associated with a 25% reduction in the odds of MACEs. These findings suggest that change in PAV could be a surrogate marker for MACEs, but given the heterogeneity in the outcomes, additional data are needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 30. doi: 10.1001/jamacardio.2023.2731. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The association between changes in atherosclerotic plaque induced by lipid-lowering therapies (LLTs) and reduction in major adverse cardiovascular events (MACEs) remains controversial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the association between coronary plaque regression assessed by intravascular ultrasound (IVUS) and MACEs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA SOURCES: A comprehensive, systematic search of publications in PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science was performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STUDY SELECTION: Clinical prospective studies of LLTs reporting change in percent atheroma volume (PAV) assessed by IVUS and describing MACE components were selected.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA EXTRACTION AND SYNTHESIS: Reporting was performed in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The association between mean change in PAV and MACEs was analyzed by meta-regression using mixed-effects, 2-level binomial logistic regression models, unadjusted and adjusted for clinical covariates, including mean age, baseline PAV, baseline low-density lipoprotein cholesterol level, and study duration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: Mean PAV change and MACE in intervention and comparator arms were assessed in an updated systematic review and meta-regression analysis of IVUS trials of LLTs that also reported MACEs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This meta-analysis included 23 studies published between July 2001 and July 2022, including 7407 patients and trial durations ranging from 11 to 104 weeks. Mean (SD) patient age ranged from 55.8 (9.8) to 70.2 (7.6) years, and the number of male patients from 245 of 507 (48.3%) to 24 of 26 (92.3%). Change in PAV across 46 study arms ranged from -5.6% to 3.1%. The number of MACEs ranged from 0 to 72 per study arm (17 groups [37%] reported no events, 9 [20%] reported 1-2 events, and 20 [43%] reported ≥3 events). In unadjusted analysis, a 1% decrease in mean PAV was associated with 17% reduced odds of MACEs (unadjusted OR, 0.83; 95% CI, 0.71-0.98; P = .03), and with a 14% reduction in MACEs in adjusted analysis (adjusted OR, 0.86; 95% CI, 0.75-1.00; P = .050). Further adjustment for cardiovascular risk factors showed a 19% reduced risk (adjusted OR, 0.81; 95% CI, 0.68-0.96; P = .01) per 1% decrease in PAV. A 1% reduction of PAV change between intervention and comparator arms within studies was also associated with a significant 25% reduction in MACEs (OR, 0.75; 95% CI, 0.56-1.00; P = .046).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this meta-analysis, regression of atherosclerotic plaque by 1% was associated with a 25% reduction in the odds of MACEs. These findings suggest that change in PAV could be a surrogate marker for MACEs, but given the heterogeneity in the outcomes, additional data are needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37647074/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37647074</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2731>10.1001/jamacardio.2023.2731</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37647074</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Iulia Iatan</dc:creator>
<dc:creator>Meijiao Guan</dc:creator>
<dc:creator>Karin H Humphries</dc:creator>
<dc:creator>Eunice Yeoh</dc:creator>
<dc:creator>G B John Mancini</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Atherosclerotic Coronary Plaque Regression and Risk of Adverse Cardiovascular Events: A Systematic Review and Updated Meta-Regression Analysis</dc:title>
<dc:identifier>pmid:37647074</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2731</dc:identifier>
</item>
<item>
<title>Erroneous Rapid Exchange Balloon Inflation During Coronary Angioplasty in a Male Patient in His 70s With Chronic Stable Angina</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37647059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 30. doi: 10.1001/jamacardio.2023.2658. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37647059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37647059</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2658>10.1001/jamacardio.2023.2658</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37647059</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Shishir K Roul</dc:creator>
<dc:creator>Avinash Arke</dc:creator>
<dc:creator>Saurabh Ajit Deshpande</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Erroneous Rapid Exchange Balloon Inflation During Coronary Angioplasty in a Male Patient in His 70s With Chronic Stable Angina</dc:title>
<dc:identifier>pmid:37647059</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2658</dc:identifier>
</item>
<item>
<title>Adverse Childhood Experiences as Social Determinants of Cardiovascular Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37647054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 30. doi: 10.1001/jamacardio.2023.2678. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37647054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37647054</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2678>10.1001/jamacardio.2023.2678</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37647054</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Adverse Childhood Experiences as Social Determinants of Cardiovascular Health</dc:title>
<dc:identifier>pmid:37647054</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2678</dc:identifier>
</item>
<item>
<title>Frailty-Guided Management of Cardiovascular Disease-From Clinical Trials to Clinical Practice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37647048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 30. doi: 10.1001/jamacardio.2023.1634. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37647048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37647048</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.1634>10.1001/jamacardio.2023.1634</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37647048</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Dae Hyun Kim</dc:creator>
<dc:creator>Lily Zhong</dc:creator>
<dc:creator>Michael W Rich</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Frailty-Guided Management of Cardiovascular Disease-From Clinical Trials to Clinical Practice</dc:title>
<dc:identifier>pmid:37647048</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.1634</dc:identifier>
</item>
<item>
<title>Modification of the GRACE Risk Score for Risk Prediction in Patients With Acute Coronary Syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37647046/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this study, using continuous rather than binary hs-cTn T at presentation, a proxy of the extent of myocardial injury, in the GRACE risk score improved the mortality risk prediction in patients with ACS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 30. doi: 10.1001/jamacardio.2023.2741. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Global Registry of Acute Coronary Events (GRACE) risk score, a guideline-recommended risk stratification tool for patients presenting with acute coronary syndromes (ACS), does not consider the extent of myocardial injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the incremental predictive value of a modified GRACE score incorporating high-sensitivity cardiac troponin (hs-cTn) T at presentation, a surrogate of the extent of myocardial injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This retrospectively designed longitudinal cohort study examined 3 independent cohorts of 9803 patients with ACS enrolled from September 2009 to December 2017; 2 ACS derivation cohorts (Heidelberg ACS cohort and Newcastle STEMI cohort) and an ACS validation cohort (SPUM-ACS study). The Heidelberg ACS cohort included 2535 and the SPUM-ACS study 4288 consecutive patients presenting with a working diagnosis of ACS. The Newcastle STEMI cohort included 2980 consecutive patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Data were analyzed from March to June 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: In-hospital, 30-day, and 1-year mortality risk estimates derived from an updated risk score that incorporates continuous hs-cTn T at presentation (modified GRACE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The predictive value of continuous hs-cTn T and modified GRACE risk score compared with the original GRACE risk score. Study end points were all-cause mortality during hospitalization and at 30 days and 1 year after the index event.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 9450 included patients, 7313 (77.4%) were male, and the mean (SD) age at presentation was 64.2 (12.6) years. Using continuous rather than binary hs-cTn T conferred improved discrimination and reclassification compared with the original GRACE score (in-hospital mortality: area under the receiver operating characteristic curve [AUC], 0.835 vs 0.741; continuous net reclassification improvement [NRI], 0.208; 30-day mortality: AUC, 0.828 vs 0.740; NRI, 0.312; 1-year mortality: AUC, 0.785 vs 0.778; NRI, 0.078) in the derivation cohort. These findings were confirmed in the validation cohort. In the pooled population of 9450 patients, modified GRACE risk score showed superior performance compared with the original GRACE risk score in terms of reclassification and discrimination for in-hospital mortality end point (AUC, 0.878 vs 0.780; NRI, 0.097), 30-day mortality end point (AUC, 0.858 vs 0.771; NRI, 0.08), and 1-year mortality end point (AUC, 0.813 vs 0.797; NRI, 0.056).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, using continuous rather than binary hs-cTn T at presentation, a proxy of the extent of myocardial injury, in the GRACE risk score improved the mortality risk prediction in patients with ACS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37647046/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37647046</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2741>10.1001/jamacardio.2023.2741</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37647046</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Georgios Georgiopoulos</dc:creator>
<dc:creator>Simon Kraler</dc:creator>
<dc:creator>Matthias Mueller-Hennessen</dc:creator>
<dc:creator>Dimitrios Delialis</dc:creator>
<dc:creator>Georgios Mavraganis</dc:creator>
<dc:creator>Kateryna Sopova</dc:creator>
<dc:creator>Florian A Wenzl</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Moritz Biener</dc:creator>
<dc:creator>Barbara E Stähli</dc:creator>
<dc:creator>Eleni Maneta</dc:creator>
<dc:creator>Luke Spray</dc:creator>
<dc:creator>Juan F Iglesias</dc:creator>
<dc:creator>Jose Coelho-Lima</dc:creator>
<dc:creator>Simon Tual-Chalot</dc:creator>
<dc:creator>Olivier Muller</dc:creator>
<dc:creator>François Mach</dc:creator>
<dc:creator>Norbert Frey</dc:creator>
<dc:creator>Daniel Duerschmied</dc:creator>
<dc:creator>Harald F Langer</dc:creator>
<dc:creator>Hugo Katus</dc:creator>
<dc:creator>Marco Roffi</dc:creator>
<dc:creator>Giovanni G Camici</dc:creator>
<dc:creator>Christian Mueller</dc:creator>
<dc:creator>Evangelos Giannitsis</dc:creator>
<dc:creator>Ioakim Spyridopoulos</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:creator>Konstantinos Stellos</dc:creator>
<dc:creator>Kimon Stamatelopoulos</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Modification of the GRACE Risk Score for Risk Prediction in Patients With Acute Coronary Syndromes</dc:title>
<dc:identifier>pmid:37647046</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2741</dc:identifier>
</item>
<item>
<title>Childhood Parental Incarceration and Adult-Onset Hypertension and Cardiovascular Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37647038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831100752&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study of US adults transitioning from young adulthood to adulthood, an increased incidence of hypertension and high-risk hsCRP, but not other cardiovascular risk factors, was observed among those exposed to parental incarceration during childhood. These findings suggest possible transgenerational health consequences of mass incarceration.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 30. doi: 10.1001/jamacardio.2023.2672. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Parental incarceration is an adverse childhood experience that disproportionately affects racially minoritized individuals and has been associated with long-term health risks. Although cardiovascular disease remains the primary cause of mortality differences between Black and White individuals in the US, the association between parental incarceration and cardiovascular risk remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the association between parental incarceration during childhood and incident cardiovascular risk in adulthood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study included data from waves IV (2008-2009) and V (2016-2018) of the US National Longitudinal Study of Adolescent to Adult Health. Participants represented US adults transitioning from young adulthood to adulthood. Data were analyzed from October 28, 2021, to May 1, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Parental incarceration was defined as a parent or parent-like figure going to jail or prison when participants were aged younger than 18 years. Outcome measures included self-reported diagnoses of obesity, hyperlipidemia, hypertension, diabetes, or heart disease as well as serum elevations in non-high-density lipoprotein cholesterol (≥160 mg/dL) and high-sensitivity C-reactive protein (hsCRP >;3 mg/L), a marker of inflammation used to estimate risk of future coronary events. Using sampling weights, incident development of each outcome was modeled as a function of parental incarceration, adjusting for participant- and neighborhood-level characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 9629 participants representing 16 077 108 US adults. Approximately half of participants were women (5498 [weighted 50.3%]) and the majority (5895 [weighted 71.4%]) were White. The mean participant age was 37.8 years (95% CI, 37.5 to 38.0 years) in wave V compared with 28.9 years (95% CI, 28.6 to 29.1 years) in wave IV. In wave V, those with childhood exposure to parental incarceration had lower educational attainment (91 [weighted 8.2%] vs 245 [weighted 4.2%] completing less than high school), had higher rates of public insurance (257 [weighted 20.6%] vs 806 [weighted 11.0%]), and were disproportionately Black (374 [weighted 22.5%] vs 1488 [weighted 13.6%]). Parental incarceration was associated with 33% higher adjusted odds (95% CI, 1.05 to 1.68) of developing hypertension and 60% higher adjusted odds (95% CI, 1.03 to 2.48) of developing elevated hsCRP. Associations between childhood parental incarceration and other diagnoses (ie, obesity, hyperlipidemia, diabetes, or heart disease) and serum lipid levels were not observed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study of US adults transitioning from young adulthood to adulthood, an increased incidence of hypertension and high-risk hsCRP, but not other cardiovascular risk factors, was observed among those exposed to parental incarceration during childhood. These findings suggest possible transgenerational health consequences of mass incarceration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37647038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831100752&v=2.17.9.post6+86293ac">37647038</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2672>10.1001/jamacardio.2023.2672</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37647038</guid>
<pubDate>Wed, 30 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Elizabeth L Tung</dc:creator>
<dc:creator>Kristen E Wroblewski</dc:creator>
<dc:creator>Jennifer A Makelarski</dc:creator>
<dc:creator>Nathaniel J Glasser</dc:creator>
<dc:creator>Stacy Tessler Lindau</dc:creator>
<dc:date>2023-08-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Childhood Parental Incarceration and Adult-Onset Hypertension and Cardiovascular Risk</dc:title>
<dc:identifier>pmid:37647038</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2672</dc:identifier>
</item>





























</channel>
</rss>